Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 11/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588896 | 0.88 | MEN1 (0.47) | MEN1NPC1RAB9AKMT2ATDP1 | |
| SCHEMBL3585178 | 0.82 | PDPK1 (0.41) | MEN1NPC1RAB9AKMT2ATDP1 | |
| SCHEMBL3587959 | 0.80 | ALOX5 (0.44) | MEN1NPC1RAB9AKMT2AADRB2 | |
| SCHEMBL3585614 | 0.79 | ADRB2 (0.46) | ADRB2ALOX5 | |
| SCHEMBL23120893 | 0.78 | MEN1 (0.53) | MEN1NPC1RAB9AKMT2ATDP1 | |
| SCHEMBL3590880 | 0.78 | ADRB2 (0.54) | ADRB2ALOX5 | |
| SCHEMBL3581733 | 0.78 | MEN1 (0.45) | MEN1NPC1RAB9AKMT2ATDP1 | |
| SCHEMBL3587698 | 0.76 | MEN1 (0.43) | MEN1NPC1RAB9AKMT2ATDP1 | |
| SCHEMBL4216337 | 0.76 | KMT2A (0.50) | MEN1NPC1RAB9AKMT2ATDP1 | |
| SCHEMBL3582152 | 0.75 | ADRB2 (0.52) | MEN1NPC1RAB9AKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7709511-B2 | Benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1915354-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018461-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | MEN1 3338/4885NPC1 1697/4885RAB9A 1073/4885 |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | MEN1 3338/4885NPC1 1697/4885RAB9A 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.